NCT05380427

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

1. To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects； 2. To evaluate the pharmacokinetic (PK) characteristics of CU-40101 liniment administered as a single and multiple topical skin application in adult male subjects with androgenic alopecia.

Conditions

• AGA

Interventions

Type	Name	Description
DRUG	CU-40101	CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Timeline

• Start date: 2022-08-15
• Primary completion: 2023-11-15
• Completion: 2024-02-22
• First posted: 2022-05-18
• Last updated: 2024-09-19

Locations

1 site across 1 country: China